The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients

[1]  J. Pignon,et al.  Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials † , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  J. Schellens,et al.  BRAF Mutations as Predictive Biomarker for Response to Anti-EGFR Monoclonal Antibodies. , 2017, The oncologist.

[3]  A. Jemal,et al.  Colorectal cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[4]  R. Schilsky,et al.  Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  J Ricke,et al.  ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  A. Orlandi,et al.  Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope. , 2015, The oncologist.

[7]  B. Massuti,et al.  First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours. , 2015, European journal of cancer.

[8]  M. Wiese,et al.  Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer , 2015, British Journal of Cancer.

[9]  D. Sargent,et al.  Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  Claudia Maggi,et al.  Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. , 2015, European journal of cancer.

[11]  J. Tabernero,et al.  547PIMPACT OF BASELINE AGE ON EFFICACY AND SAFETY OF FIRST-LINE PANITUMUMAB (PMAB) + FOLFOX4 VS FOLFOX4 TREATMENT. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  I. Browner,et al.  Refining the chemotherapy approach for older patients with colon cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  C. García-Girón,et al.  First-line bevacizumab and capecitabine–oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study , 2014, British Journal of Cancer.

[14]  D. Shin,et al.  Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. , 2013, The Lancet. Oncology.

[15]  J. Tabernero,et al.  Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. , 2013, The New England journal of medicine.

[16]  O. Bouché,et al.  Geriatric factors predict chemotherapy feasibility: ancillary results of FFCD 2001-02 phase III study in first-line chemotherapy for metastatic colorectal cancer in elderly patients. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  C. Tournigand,et al.  External validation of the G-8 geriatric screening tool to identify vulnerable elderly cancer patients: The ELCAPA-02 study , 2012 .

[18]  S. Mathoulin-Pélissier,et al.  Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  G. Lyman,et al.  Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High‐Age Patients (CRASH) score , 2012, Cancer.

[20]  M. Parmar,et al.  Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial , 2011, The Lancet.

[21]  Enrico Domingo,et al.  BRAF (v-raf murine sarcoma viral oncogene homolog B1) , 2011 .

[22]  H. Sorbye,et al.  Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients , 2009, Cancer.

[23]  V. Heinemann,et al.  The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials. , 2017, European journal of cancer.

[24]  H. Wildiers,et al.  Performance of two geriatric screening tools in older patients with cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.